Data Supplement

• Supplemental Data -

  Supplementary Figure 1 -   Inhibitory effects of kratom extracts (coded K-50, K-51, and K-52) and mitragynine on
  cytochrome P450 (CYP) 2C9 (diclofenac 4′-hydroxylation) (A), CYP2D6 (dextromethorphan Odemethylation) (B), and CYP3A (midazolam 1′-hydroxylation) (C) activities in HLMs and CYP3A (D) activity in HIMs. Extracts were tested at 2, 10, and 20 µg/mL; mitragynine was tested at 1, 10, and 100 µM. Positive control inhibitors included sulfaphenazole (1 µM), quinidine (2 µM), and ketoconazole (0.1 µM) for CYP2C9, CYP2D6, and CYP3A, respectively.
  

  Supplementary Figure 2 - Representative Lineweaver–Burk plot showing inhibition of CYP2D6-mediated
  dextromethorphan O-demethylation by mitragynine (0.37-10 µM) in HLMs.